Archives March 2026

• 45% of C-level executives plan to establish a U.S. legal entity within the next 12 months; a further 27% say they will consider entry within two to three years
• 65% cite supply chain or manufacturing efficiency as the primary driver for U.S. expansion
• 88% identify federal and state tax reporting as the most burdensome area of U.S. compliance

Nearly half (45%) of global C-suite leaders plan to establish a legal entity in the United States within the next 12 months, highlighting continued demand for access to the U.S. market. This finding from the latest research by CSC—the leading provider of global business administration and compliance solutions—demonstrates the U.S. continues to attract investment from around the world, even as companies face an increasingly complex regulatory landscape.

CSC surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to examine global sentiment toward U.S. market entry, including expansion plans, strategic drivers, and regulatory challenges.¹ CSC’s report Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses details the results.

The research highlights strong forward momentum toward U.S. expansion. In addition to the 45% planning to establish an entity within the next 12 months, a further 27% say they will consider entry over the next two to three years.

Operational and strategic benefits are the dominant drivers for expansion. Almost two-thirds of the executives (65%) cite supply chain or manufacturing efficiency as the main motivation for establishing a U.S. presence. Strategic positioning—including partnerships and mergers and acquisitions opportunities—is cited by 56% of respondents, while 56% also highlight access to capital markets as a key motivator.

“We’re seeing a clear trend of U.K., European, and Asia-Pacific multinationals incorporating a U.S. entity to reach the approximately 340 million consumers or investors in the U.S.,” said Myrna Reijnders, market leader, Americas at CSC. “It’s a significant movement across sectors—from retail, real estate, insurance, healthcare, and biotech to energy, AI, and technology, including critical infrastructure, such as data centers.”

Despite strong enthusiasm, companies acknowledge entering the U.S. market is far from straightforward. Almost nine-in-10 (88%) respondents view federal and state tax reporting as the most burdensome compliance requirement, followed closely by employment and labor regulations (80%).

Many companies underestimate the realities of operating in the U.S. Half (50%) of companies with some degree of U.S. presence say they were surprised by the complexity of tax and financial reporting requirements once operations were underway.

As a result, they increasingly see outsourcing as a practical strategy for managing compliance and operational risk. A significant 79% of executives indicate they will likely outsource U.S. compliance or governance functions to a specialist provider, with 62% stating this is “very likely.”

“Companies assume doing business in the U.S. means you’re working in one jurisdiction. But rules and requirements can vary at the federal, state, and local levels,” added Jenn Kenton, chief commercial officer at CSC. “That’s where the challenge lies. Successfully setting up and maintaining a U.S. business means navigating those differences. It’s also where CSC has supported companies for over 125 years. Our goal is to ensure companies are set up to operate and remain compliant in the U.S. and beyond.”

CSC has been helping organizations incorporate, operate, and maintain compliance in the United States since 1899. Today, the company provides U.S. governance and compliance services, including registered agent representation in all 50 states, entity formation and management, annual report filing, business license management, and compliance monitoring to help organizations maintain good standing.

To download a copy of CSC’s Navigating U.S. Market Entry: Insights, Risks, and Opportunities for Global Businesses, visit cscglobal.com/service/campaigns/us-market-entry-report/

¹CSC, in partnership with PureProfile, surveyed 300 C-level executives at large organizations headquartered in Europe, the U.K., Asia Pacific, and South America to understand their strategies, priorities, and challenges when expanding into the United States.

About CSC

CSC is the leading provider of business administration and compliance solutions, offering industry-leading expertise and unmatched global reach to alternative fund managers and capital markets participants. Leveraging deep institutional experience and a tailored approach, CSC delivers a comprehensive suite of fund administration, trust, agency, and compliance services to support a wide range of private and public market transactions, complex fund strategies, and scalable operations.

As the trusted partner of choice for more than 75% of the PEI 300 and 90% of the Fortune 500^®, CSC helps clients navigate operational and transactional complexities across more than 140 jurisdictions and various asset classes. With extensive worldwide capabilities, our expert teams provide solutions tailored to each client’s needs. Privately held and professionally managed since 1899, we combine global reach, local expertise, and innovative solutions to help our clients succeed.

We are the business behind business^®. Learn more at cscglobal.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326233249/en/

Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/

Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal.

The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context of the disruption caused by ongoing geopolitical events.

Both parties welcome this agreement, as it further consolidates long‑term deliveries and enhances the commercial partnership between Venture Global and Edison which is an important foundational customer of the Calcasieu Pass project. The parties look forward to continuing to work together to pursue Venture Global’s mission of stabilizing global LNG/gas markets and to further consolidate Edison’s role in guaranteeing the stability and security of Italy’s energy supply.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326559130/en/

Netflix is forecast to reach over 1 billion monthly active users globally by 2027, while YouTube is expected to approach 3 billion users worldwide according to Omdia.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326155411/en/

Netflix and YouTube are the first choice video services in France

The new data, presented by Maria Rua Aguete, Head of Media & Entertainment at Omdia, at Series Mania, showcases how global platforms are reshaping video consumption across Europe.

During her session with Justine Ryst, Managing Director of YouTube France and Southern Europe, Aguete highlighted that Netflix and YouTube are the leading first-choice options for video services in France, ahead of traditional broadcasters and pay TV. Netflix leads the market at 18%, followed by YouTube at 12%.

The session, “How to Turn YouTube into an Asset for Your Series?”, underlined the evolving role of YouTube in the content ecosystem. While there is significant audience overlap between YouTube and major French broadcasters such as France TV, TF1+, and M6+, the data also shows that a substantial portion of YouTube’s audience sits outside these services, making it a critical platform for incremental reach.

This dual-dynamic positions YouTube as both a complementary platform – enhancing reach among existing TV audiences – and a gateway to new viewers that broadcasters may not otherwise capture.

In the UK, the market reflects a balanced ecosystem between global and local players. Netflix (17%), Sky (15%), and YouTube (9%) rank as the leading first-choice services, highlighting the continued relevance of premium pay TV alongside streaming.

“Scale and reach are critical, but so is complementarity. Platforms like YouTube not only amplify content but also unlock entirely new audiences, while Netflix continues to lead in premium storytelling and engagement,” said Rua Aguete.

The findings reinforce a key industry shift: success increasingly depends on combining global scale with local relevance, leveraging platforms not just as competitors, but as strategic partners to grow total audiences.

ABOUT OMDIA

Omdia, part of TechTarget, Inc. d/b/a Informa TechTarget (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets grounded in real conversations with industry leaders and hundreds of thousands of data points, make our market intelligence our clients’ strategic advantage. From R&D to ROI, we identify the greatest opportunities and move the industry forward.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326155411/en/

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027.

This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone.

Dr. Yuelei Shen, President and CEO of Biocytogen, said: “We are pleased to see one of our partnered molecules reach this important stage of development. This milestone further validates the quality, developability, and therapeutic potential of fully human bispecific antibodies discovered using our RenLite^® platform, which features a common light chain design. We look forward to the continued clinical advancement of the program.”

About Biocytogen

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

Biocytogen has independently developed its proprietary RenMice^® (RenMab^®/RenLite^®/RenNano^®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. “As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs).”Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326831022/en/

• The Phase 1 study of RLS-1496, the first human trial of a GPX4 (selective glutathione peroxidase 4) modulator, met its primary endpoint and also demonstrated a statistically significant relationship between target engagement and clinical improvement in psoriasis and atopic dermatitis

• RLS-1496 is a first-in-class disease-modifying mechanism targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases of aging

• A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States, with completion expected later this year

• Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD, to moderate panel on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology (AAD) annual meeting on Thursday, March 26, at 1:05 pm MT in Denver

• Oral presentation of data accepted at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial in patients with plaque psoriasis, atopic dermatitis, and skin aging (photo-aged skin). The recently completed Phase 1 clinical trial, conducted in the European Union, was designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496—the first-ever GPX4 (selective glutathione peroxidase 4) modulator to be studied in human trials, and the first specifically targeting cellular rejuvenation, an area of great interest to the scientific community as a new therapeutic pathway. The study met its primary endpoint, with RLS-1496 also demonstrating early signs of efficacy.

Preliminary Trial Results

• RLS-1496 was well-tolerated, with no serious adverse events (AEs) and no discontinuations due to AEs or tolerability issues during the 4-week study
• In psoriasis patients:
  • Clear dose-response seen during the trial (0.1%, 0.5%, and 1.0%); all doses were well-tolerated so only 1.0% dose will be evaluated moving forward
  • Dose-related target engagement of RLS-1496 and GPX4
  • Overall reduction in senescent cells seen with RLS-1496 in the mid- and high-dose cohorts
  • Some subjects treated with RLS-1496 had a reduction of senescent cells, which was associated with a reduction of inflammatory cytokines such as IL-19 and S100A7; this reduction was not seen in the vehicle cohort
  • An average 20% reduction in epidermal thickness was observed on histology in subjects treated with RLS-1496 for one month
  • A statistically significant relationship was seen between target engagement and improvement in clinical psoriasis severity
• In atopic dermatitis patients:
  • Even higher levels of target engagement and substantial clinical improvement were seen in atopic dermatitis subjects on RLS-1496
  • After one month of treatment, 25% of subjects on RLS-1496 had a >/=4-point change in pruritus (or itching) on the numeric rating scale (NRS); no vehicle subjects had a 4-point or more change on the NRS
• Early photo-aging data show:
  • Dose-dependent target engagement in non-lesional photo-aged skin
  • Histology, proteomics, and spatial transcriptomics indicate that collagen gene and protein expression increase with treatments over time, in particular, spatial transcriptomics shows an effect in dermal fibroblasts
  • Spatial transcriptomics show indication that SASPs and inflammatory biomarkers decrease with treatments over time in keratinocytes

“We’re pleased by the positive safety and tolerability seen in the trial, with the additional preliminary results exceeding our expectations by showing very promising and clinically meaningful results across multiple measures including histologic, cellular, biomarker, and clinical evaluations in psoriasis, atopic dermatitis, and photo-aged skin,” said Rubedo CEO Frederick Beddingfield, III, MD, PhD, FAAD. “It’s uncommon to see clinical effect in a Phase 1 dermatology study given the shorter study duration and smaller sample size, and we are excited by the potential of this treatment with the clinical and biomarker changes we have observed already.”

Dr. Beddingfield will preview these results during a panel he will moderate on senescence and skin at the Dermatology Innovation Forum (DIF) during the American Academy of Dermatology annual meeting on Thursday, March 26, at 1:05 pm MT in Denver. Additional results from this trial will be presented during an oral presentation at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago.

A second study for RLS-1496 – a Phase 1b/2a study in actinic keratosis (precancerous skin lesions) – is underway in the United States with completion expected later this year. In both trials, all subjects have their photo-aged skin treated with RLS-1496 in addition to their lesional skin relating to their medical condition. From these trials, Rubedo expects to obtain a large dataset on the treatment of aging skin from approximately 70 subjects.

Rubedo Chief Scientific Officer and Founder Marco Quarta, PhD, said, “This is one of the first comprehensively evaluated trials of a senotherapeutic drug that targets aging pathologic cells and regenerates healthy cells, and also the first human trial of a GPX4 modulator. These preliminary results show the drug working mechanistically as expected and even better than should be expected clinically in a 4-week trial. We are excited for the upcoming comprehensive results from this trial, as well as the results of the ongoing trial in actinic keratosis.”

About RLS-1496 and GPX4 Modulation

Rubedo’s lead candidate RLS-1496, being developed for topical and oral administration, is a potential first-in-class, disease-modifying GPX4 modulator selectively targeting pathologic senescent or “aged” cells that drive chronic degenerative diseases and conditions associated with biological aging processes. These include immunology and inflammation (I&I), dermatology and skin aging, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.

In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an Achilles heel of senescent cells. By modulating GPX4 in ferroptosis-sensitive senescent “aged” cells, RLS-1496 may be able to clear these cells to not only fight disease, but also support healthy cells to function properly and restore tissue homeostasis. Beyond its targeted senolytic function in triggering selective ferroptosis within pathological senescent cells, RLS-1496 could also act as a restorative modulator that induces a vital ‘redox-reset’ in stressed neighboring cells, effectively clearing the source of chronic inflammation while actively re-establishing healthy tissue homeostasis.

RLS-1496 uses Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets.

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326810310/en/

M1X Global, a sovereign financial infrastructure and technology company, today announced its public launch alongside the close of an oversubscribed $3 million angel round. The funding, spanning strategic investments and grants, will support platform development and accelerate regulated institutional adoption of USDM1, the first USD-denominated, treasury collateralized sovereign debt instrument issued natively by a sovereign on public blockchain infrastructure.

The $3 million in funding drew participation from leading figures across global capital markets and digital asset infrastructure, including Balaji Srinivasan, former CTO of Coinbase; Tama Churchouse, CEO of Cumberland Labs; Richard Gorelick, former Head of Market Structure at DRW; and Dan Robichaud, former CIO at Intel. Institutional participation from FJ Labs and grant funding from Stellar Development Foundation reflect strong alignment between private capital and mission-driven partners advancing blockchain-based market development.

M1X Global is building infrastructure that enables governments to issue and manage financial instruments natively on-chain while maintaining compatibility with global institutional frameworks. Its flagship initiative, USDM1, developed in public-private partnership with the Republic of the Marshall Islands (RMI), provides a working example of this model. Issued directly by the government of the RMI, USDM1 is a U.S. dollar-denominated sovereign bond fully collateralized (1:1) by short-duration U.S. Treasury instruments and structured under New York law, designed to provide holders with a perfected first-priority security interest in collateral. USDM1 is not a tokenized or wrapped instrument and maintains programmable, 24/7 settlement.

USDM1 supports the world’s first nationwide Universal Basic Income program as a disbursement rail in the RMI, enabling instant delivery of funds to citizens via the Lomalo digital wallet across one of the world’s most geographically dispersed island nations.

Mark Lurie, Co-Founder and Chief Executive Officer of M1X Global, said:“M1X Global is focused on modernizing sovereign financial infrastructure for a digital, always-on capital market environment. With USDM1, we’ve demonstrated how sovereign debt can be issued as a programmable, digitally native instrument without compromising institutional standards. This funding allows us to scale that model and deepen integration across government use and institutional markets.”

Jordan Goldman, Co-Founder and COO of M1X Global, added: “USDM1 was structured to function across domestic and regulated institutional markets. As a Treasury-backed sovereign financial instrument with look-through maintained, it can serve as high-quality collateral – improving capital efficiency and optimizing balance sheet treatment across 24/7 institutional trading and financing workflows.”

Dr. Peter Dittus, former Secretary General of the Bank for International Settlements and M1X Global advisor, said:“USDM1 applies established sovereign debt principles in a digitally native format that supports institutional capital treatment. This is a critical distinction from privately issued digital dollar instruments – and one that enables broader adoption across regulated financial institutions.”

Following its public launch, M1X Global is coordinating and scaling regulated institutional use of USDM1. By combining sovereign exposure with U.S. Treasury collateralization, USDM1 introduces a new category of digitally native, collateralized sovereign debt that integrates with trading, financing, and liquidity workflows with institutional compatibility and legal certainty.

Proceeds from the round will fund expanded institutional access for USDM1, pilot programs with derivatives and capital markets participants, and continued development of M1X Global’s platform for sovereign issuers operating in 24/7 on-chain markets. M1X Global’s advisory board includes Dr. Peter Dittus supporting capital treatment and regulatory positioning and Leon Marshall, former CEO Europe at Galaxy Digital (Nasdaq: GLXY), supporting institutional distribution and market development.

ENDS

About M1X Global

M1X Global is a sovereign financial infrastructure and technology company bridging public finance and on-chain capital markets. Operating in public-private partnership with the Republic of the Marshall Islands, M1X coordinates legal, compliance, technology, custody and institutional infrastructure required to integrate sovereign digital instruments and global markets.

About USDM1

USDM1 is USD-denominated sovereign debt issued natively on-chain by the Republic of the Marshall Islands, secured 1:1 by short-duration U.S. Treasury instruments held in bankruptcy remote custody. The RMI operates exclusively on the U.S. dollar standard under its Compact of Free Association with the United States, which establishes the dollar as its sole legal tender. For more, see the government’s white-paper “Financial Access and the Path to USDM1.”

USDM1 is structured in the style of a fully collateralized Brady bond under New York law, with an explicit customary waiver of sovereign immunity. USDM1 provides holders with a perfected first-priority security interest in collateral. Unlike privately issued digital dollar instruments, USDM1 is structured as sovereign debt with collateral perfected by control under UCC, enabling compatibility with ISDA netting frameworks and supporting inclusion in ISDA netting sets. As institutional-grade collateral, USDM1 supports integration in institutional margin, repo and financing workflows and operates within existing legal, accounting, and capital frameworks, improving capital efficiency and balance sheet treatment.

Cleary Gottlieb serves as issuer’s counsel and advised with respect to the structuring of the instrument under New York law with the participation of partners specializing in sovereign debt, UCC and secured transactions, creditors’ rights, netting and digital asset market infrastructure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260326536769/en/